Sign In
Buy KRYS
$301.82
+8.61 (+2.94%)
At Close: Jun 03, 2026
Surging Earnings Estimates Signal Upside for Krystal Biotech (KRYS) Stock
01:21pm, Tuesday, 03'rd Sep 2024
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Krystal Biotech Stock Surges 21.9% in 3 Months: More Room to Grow?
02:31pm, Friday, 30'th Aug 2024
KRYS has gained 21.9% in the past three months on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
Krystal Biotech, Inc. (KRYS) Q2 2024 Earnings Call Transcript
08:10pm, Friday, 09'th Aug 2024
Krystal Biotech, Inc. (NASDAQ:KRYS ) Q2 2024 Earnings Conference Call August 5, 2024 8:30 AM ET Company Participants Stéphane Paquette - Vice President, Corporate Development Krish Krishnan - Chairma
Best Momentum Stock to Buy for August 8th
08:26am, Thursday, 08'th Aug 2024
KRYS and AMAL made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2024.
New Strong Buy Stocks for August 8th
07:10am, Thursday, 08'th Aug 2024
MTH, ULS, KRYS, RCL and DRVN have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2024.
Krystal Biotech (KRYS) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Wednesday, 07'th Aug 2024
Krystal Biotech (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Top Estimates
10:15am, Monday, 05'th Aug 2024
Krystal Biotech, Inc. (KRYS) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to loss of $1.25 per share a year ago.
Krystal Biotech: High Valuation Merits Caution Ahead Of Q2 Earnings (Rating Downgrade)
11:13pm, Tuesday, 30'th Jul 2024
Krystal Biotech's Q1 2024 revenue increased to $45.25 million but fell short of analyst expectations of $47.37 million. Analysts expect Q2 earnings to be $65.49 million. Vyjuvek's patient adherence ra
5 Biotech Stocks to Bet On Bright Industry Prospects
10:45am, Monday, 29'th Jul 2024
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, S
Krystal Biotech to Report Second Quarter 2024 Financial Results on August 5, 2024
08:00am, Friday, 26'th Jul 2024
PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter
Krystal Biotech (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
09:51am, Thursday, 18'th Jul 2024
Krystal Biotech (KRYS) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it thro
Earnings Estimates Moving Higher for Krystal Biotech (KRYS): Time to Buy?
01:21pm, Thursday, 23'rd May 2024
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Krystal Biotech (KRYS) Gains 36% Year to Date: Here's Why
12:11pm, Thursday, 23'rd May 2024
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB
08:08am, Wednesday, 15'th May 2024
Krystal Biotech: VYJUVEK's Blockbuster Potential In Gene Therapy For DEB
Krystal Biotech to Present at the American Thoracic Society 2024 International Conference
07:00am, Wednesday, 15'th May 2024
PITTSBURGH, May 15, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, announced today that the Company will be presenting new
